Literature DB >> 2117161

The molecular structure and pathology of alpha 1-antitrypsin.

R W Carell1.   

Abstract

Antitrypsin is the predominant protease inhibitor in human plasma. Despite its name, its prime function is an inhibitor of neutrophil elastase. It is the archetype of a family of protease inhibitors (serpins) characteristically with a MW 50,000 and a highly ordered tertiary structure. Its role is as a protector of vulnerable tissues against digestion by leukocyte enzymes, and plasma deficiency predisposes to premature emphysema. Northern Europeans are uniquely susceptible to deficiency due to the frequency of two mutants (Z & S) both having substitutions at glutamic acids that form key salt bridges in the molecule. In the reactive center of antitrypsin is a labile methionine which allows leucocytes to switch off inhibitory activity but this contributes to the accelerated lung degeneration in cigarette smokers. Although plasma replacement therapy is one option for treatment a first approach is to avoid smoking and other environmental irritants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117161     DOI: 10.1007/bf02718175

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  6 in total

Review 1.  The molecular pathology of the serpins.

Authors:  R W Carrell; K S Aulak; M C Owen
Journal:  Mol Biol Med       Date:  1989-02

Review 2.  alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage.

Authors:  R W Carrell
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

Review 3.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

4.  DNA restriction fragments associated with alpha 1-antitrypsin indicate a single origin for deficiency allele PI Z.

Authors:  D W Cox; S L Woo; T Mansfield
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

Review 5.  Molecular basis of alpha-1-antitrypsin deficiency.

Authors:  M Brantly; T Nukiwa; R G Crystal
Journal:  Am J Med       Date:  1988-06-24       Impact factor: 4.965

6.  Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function.

Authors:  H Loebermann; R Tokuoka; J Deisenhofer; R Huber
Journal:  J Mol Biol       Date:  1984-08-15       Impact factor: 5.469

  6 in total
  3 in total

Review 1.  Future developments in the pharmacotherapy of lung disease.

Authors:  A Van der Kuy
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

2.  Detection of serine proteases in extracts of the domestic mite Blomia tropicalis.

Authors:  Federico Montealegre; Carmen Quiñones; Nanette Torres; Kirsteen Goth
Journal:  Exp Appl Acarol       Date:  2002       Impact factor: 2.380

3.  Human Alpha-1-Antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury.

Authors:  Nuria Maicas; Johan van der Vlag; Janin Bublitz; Sandrine Florquin; Marinka Bakker-van Bebber; Charles A Dinarello; Vivienne Verweij; Roos Masereeuw; Leo A Joosten; Luuk B Hilbrands
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.